Pires Diana P, Costa Ana Rita, Pinto Graça, Meneses Luciana, Azeredo Joana
CEB - Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
Department of Bionanoscience, Kavli Institute of Nanoscience, Delft University of Technology, Van der Maasweg 9, 2629 HZ, Delft, Netherlands.
FEMS Microbiol Rev. 2020 Nov 24;44(6):684-700. doi: 10.1093/femsre/fuaa017.
Antibiotic resistance is a major public health challenge worldwide, whose implications for global health might be devastating if novel antibacterial strategies are not quickly developed. As natural predators of bacteria, (bacterio)phages may play an essential role in escaping such a dreadful future. The rising problem of antibiotic resistance has revived the interest in phage therapy and important developments have been achieved over the last years. But where do we stand today and what can we expect from phage therapy in the future? This is the question we set to answer in this review. Here, we scour the outcomes of human phage therapy clinical trials and case reports, and address the major barriers that stand in the way of using phages in clinical settings. We particularly address the potential of phage resistance to hinder phage therapy and discuss future avenues to explore the full capacity of phage therapy.
抗生素耐药性是全球主要的公共卫生挑战，如果不能迅速开发出新的抗菌策略，其对全球健康的影响可能是毁灭性的。作为细菌的天然捕食者，噬菌体可能在避免这样可怕的未来中发挥重要作用。抗生素耐药性问题的日益严重，重新唤起了人们对噬菌体疗法的兴趣，并且在过去几年中已经取得了重要进展。但我们如今处于什么阶段，未来又能从噬菌体疗法中期待什么？这就是我们在本综述中要回答的问题。在这里，我们梳理了人类噬菌体疗法临床试验和病例报告的结果，并探讨了在临床环境中使用噬菌体的主要障碍。我们特别讨论了噬菌体耐药性阻碍噬菌体疗法的可能性，并探讨了未来充分发挥噬菌体疗法潜力的途径。
